Piramal Pharma Ltd. News, Corporate filings and Earnings/Conference Calls

Keep track of all breaking news and updates on Piramal Pharma Ltd. from all sources in a single place.

Load latest

Piramal Pharma Ltd.

13 Jan 2025

196.69

1.49%

Board Meeting

Piramal Pharma Ltd - 543635 - Board Meeting Intimation for Intimation As Per Regulation 29 Of …

BSE India

Piramal Pharma Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 28/01/2025 ,inter alia, to consider and approve Unaudited Financial Results (Standalone and Consolidated) for the quarter ended 31st December, 2024

pdf

Piramal Pharma Ltd.

06 Jan 2025

196.69

1.49%

Company Update

Piramal Pharma Ltd - 543635 - Announcement under Regulation 30 (LODR)-Change in Management

BSE India

Disclosure under regulation 30 of the SEBI (Listing Obligations and Disclsoure Requirements), 2015 as amended (''SEBI Listing Regulations'') - Appointment of Senior Management Personnel

pdf

Piramal Pharma Ltd.

02 Jan 2025

196.69

1.49%

Company Update

Piramal Pharma Ltd - 543635 - Intimation For Change In The Name Of The Registrar And …

BSE India

Intimation for change in the name of the Registrar and Share Transfer Agent of the Company.

pdf

Piramal Pharma Ltd.

02 Jan 2025

196.69

1.49%

Company Update

Piramal Pharma Ltd - 543635 - Intimation Regarding Change Of Name Of Registrar And Transfer Agent …

BSE India

Intimation regarding change of name of Registrar and Transfer Agent (''RTA'') of the Company from "Link Intime India Private Limited" to "MUFG Intime India Private Limited."

pdf

Piramal Pharma Ltd.

17 Dec 2024

196.69

1.49%

Piramal Pharma share price jumps 4.5% after JM Financial issues 'buy' rating, sees 36% upside

livemint

JM Financial has initiated coverage on Piramal Pharma with a 'Buy' rating and a target price of 340, reflecting a 36% upside potential. The firm anticipates over 17% CAGR growth in Piramal's CDMO business, driven by strong demand and competitive advantages in the expanding CRDMO industry.

Number of FII/FPI investors decreased from 257 to 247 in Jun 2025 qtr

Piramal Pharma up 7% as JM Financial initiates with 'Buy'; 36% upside eyed

Business Standard | 17 Dec 2024 1 more

Piramal Pharma Ltd.

07 Dec 2024

196.69

1.49%

Piramal Pharma to pay $407,400 to US-based VetDC Inc to settle dispute

Business Standard

Piramal Pharma on Friday said it will pay USD 407,400 to US-based VetDC, Inc to settle a dispute over rejected batches of a product. Piramal Pharma Solutions Inc, a unit of the company, and VetDC, Inc have entered into a settlement agreement for an amount of USD 407,400, the drug maker said in a regulatory filing. VetDC had claimed damages on account of rejection of certain batches of product manufactured and supplied by Piramal Pharma Solutions Inc. "While the company continues to believe that its legal stand is appropriate against claims made by VetDC and maintains that it has defence to VetDC's claims of liabilities and damages, in order to solely avoid continued legal costs and uncertainties of protracted litigation, the Company and VetDC have both decided to settle," Piramal Pharma said. The company shall have no responsibility for any other costs beyond the amount of USD 407,400, it added. "This settlement will not have a significant impact on the financial position of the .

Piramal Pharma Ltd.'s price crossed above 50Day SMA today

Piramal Pharma Ltd.

06 Dec 2024

196.69

1.49%

Company Update

Piramal Pharma Ltd - 543635 - Intimation Under Regulation 30 Of The SEBI (Listing Obligations And …

BSE India

Intimation under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 ("SEBI Listing Regulations") - Update on Liitigation

pdf

Piramal Pharma Ltd.

08 Nov 2024, 04:05PM

196.69

1.49%

Company Update

Piramal Pharma Ltd - 543635 - Intimation Under Regulation 30 Of The Securities And Exchange Board …

BSE India

Intimation under Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclsoure Requirements) Regulations, 2015, as amended (''SEBI listing Regulations) - Issuance of Corporate Guarantee.

pdf

Piramal Pharma Ltd.

31 Oct 2024

196.69

1.49%

Piramal Pharma stock hits new, soars 25% in 6 days on strong Q2 results

Business Standard

Over the long term, the management remains committed to achieving the company's financial goals of $2 billion revenue with 25 per cent EBITDA margin and 1x net debt / EBITDA by FY30.